Cargando…

The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease

Allogeneic hematopoietic stem cell transplant is an established treatment modality for hematologic and non-hematologic diseases. However, it is associated with acute and long-term sequelae which can translate into mortality. Graft-versus-host disease (GVHD) remains a glaring obstacle, especially wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Robert, Ramdial, Jeremy, Algaze, Sandra, Beitinjaneh, Amer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744091/ https://www.ncbi.nlm.nih.gov/pubmed/29186076 http://dx.doi.org/10.3390/biomedicines5040067

Ejemplares similares

Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models
por: Mashima, Kiyomi, et al.
Publicado: (2021)

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis
por: Zuckermann, Joice, et al.
Publicado: (2023)

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in the Prophylaxis of Graft-Versus-Host Disease: A Systematic Review
por: Dybko, Jarosław, et al.
Publicado: (2023)

Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia
por: Keogh, Steven J., et al.
Publicado: (2022)

A phase II study of sirolimus, tacrolimus, and rabbit anti-thymocyte globulin as graft-versus-host prophylaxis after unrelated-donor peripheral blood stem cell transplant
por: Khaled, Samer K., et al.
Publicado: (2012)

Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
por: Butera, Sara, et al.
Publicado: (2021)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis
por: Salas, Maria Queralt, et al.
Publicado: (2019)

Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy
por: Ko, Eun Jeong, et al.
Publicado: (2019)

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
por: Nagler, Arnon, et al.
Publicado: (2020)

Anti-thymocyte globulin in haematology: Recent developments
por: Siddiqui, Salahuddin, et al.
Publicado: (2019)

HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation
por: Clausen, Johannes, et al.
Publicado: (2017)

Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
por: Binder, Christian, et al.
Publicado: (2020)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation
por: Kim, Taeyun, et al.
Publicado: (2020)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood
por: Xu, Xiaoqian, et al.
Publicado: (2020)

Does rabbit anti-thymocyte globulin dose and antiviral prophylaxis alter the risk of the development of PTLD in renal transplant population?
por: Mohamed, Mahmoud, et al.
Publicado: (2020)

Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors
por: Li, Ting, et al.
Publicado: (2022)

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
por: Fang, Shu, et al.
Publicado: (2022)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007)

Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation
por: Alloway, Rita R., et al.
Publicado: (2019)

Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin
por: Suk Lee, Young, et al.
Publicado: (2019)

Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis
por: Yang, Xue, et al.
Publicado: (2021)

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023)

Serotherapy of a spontaneous mouse tumour.
por: O'Neill, G. J.
Publicado: (1980)

Paths to the discovery of antivenom serotherapy in France
por: Bochner, Rosany
Publicado: (2016)

Potential and challenges of serotherapy for severe influenza
por: Lee, Nelson, et al.
Publicado: (2017)

Antigangrenous Serotherapy by a Multivalent Serum
Publicado: (1918)

Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
por: Tjon, Jennifer M.-L., et al.
Publicado: (2021)

Anti‐thymocyte globulin‐mediated immunosenescent alterations of T cells in kidney transplant patients
por: Lee, Ga Hye, et al.
Publicado: (2022)

Fludarabine–Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia
por: Salamonowicz-Bodzioch, Małgorzata, et al.
Publicado: (2021)

Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin
por: Kanda, Junya, et al.
Publicado: (2020)

Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation
por: Resende, C.B., et al.
Publicado: (2017)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Pre-Transplant Total Lymphocyte Count Determines Anti-Thymocyte Globulin Exposure, Modifying Graft-versus-Host Disease Incidence and Post-Transplant Thymic Restoration: A Single-Center Retrospective Study
por: Grasso, Antonio Giacomo, et al.
Publicado: (2023)

Anti-thymocyte globulin induced non-cardiogenic pulmonary edema during renal transplantation
por: Parikh, Beena K., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1d1i98krksf69g4do5ll86dv6c